Skip to main content

Poolbeg Pharma "couldn't be happier" with POLB 001 human challenge trial data

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive's Thomas Warner after announcing the data readout from an LPS human challenge trial for POLB 001, the infectious disease focused biopharma company's lead molecule.

Skillington says that he "couldn't be happier" with the results, that he says will help "ramp up the discussions" with potential partners.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-couldnt-be-happier-with-polb-001-human-challenge-trial-data-264590133

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  250.56
+0.86 (0.34%)
AAPL  270.23
+6.83 (2.59%)
AMD  278.39
+0.13 (0.05%)
BAC  53.91
+0.40 (0.75%)
GOOG  339.40
+6.63 (1.99%)
META  688.55
+11.68 (1.73%)
MSFT  422.79
+2.53 (0.60%)
NVDA  201.68
+3.33 (1.68%)
ORCL  175.06
-3.28 (-1.84%)
TSLA  400.62
+11.72 (3.01%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.